Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

Phase 2 Unknown 770 enrolled Korea University Guro Hospital Korean Center for Disease Control and Prevention · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03 in adults aged 19 years and older who received a primary series of vaccination or the 1st booster vaccination against COVID-19 approved in Korea.

Timeline

Start: 2022-01-24
Primary completion: 2023-08
Completion: 2023-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GBP510	Vaccine	25 ug	—

Indications

No indication recorded.